Literature DB >> 26348464

The Effects of HSP27 on Gemcitabine-Resistant Pancreatic Cancer Cell Line Through Snail.

Song Zhang1, Xiao-qi Zhang, Shu-ling Huang, Min Chen, Shan-shan Shen, Xi-wei Ding, Ying Lv, Xiao-ping Zou.   

Abstract

OBJECTIVES: To evaluate the regulation mechanism of heat shock protein 27 (HSP27) on gemcitabine (GEM) resistance of pancreatic cancer cell.
METHODS: The expression vectors pEGFP-C1-HSP27 and the vectors of MicroRNA targeting Snail were introduced into GEM-sensitive pancreatic cancer SW1990 cells, and the vectors of small hairpin RNA targeting HSP27 were transfected into SW1990 and GEM-resistant SW1990/GEM cells. The expressions of HSP27, p-HSP27 (Ser82), Snail, ERCC1, and E-cadherin were evaluated by Western blotting. The sensitivity of transfected cells to GEM was detected by CCK-8 assay and Annexin V-FITC apoptosis assay.
RESULTS: As compared to SW1990, SW1990/GEM showed significantly increased expressions of HSP27, p-HSP27, Snail and ERCC1 with decreased expression of E-cadherin. By increasing HSP27 expression, we found increase of Snail and ERCC1 with reduction of E-cadherin expressions, while reduction of HSP27 expression caused reduction of Snail and ERCC1 but increase of E-cadherin expressions. Downregulation of Snail resulted in the reduction of ERCC1 expression and increase of E-cadherin. Furthermore, downregulation of HSP27 or snail caused increased GEM sensitivity of pancreatic cancer cells, and upregulation of HSP27 showed the opposite results.
CONCLUSIONS: There is an inverse correlation between HSP27 expression and GEM sensitivity of SW1990 cells, which might be realized by regulating E-cadherin and ERCC1 expressions through Snail.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26348464     DOI: 10.1097/MPA.0000000000000418

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  9 in total

1.  A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.

Authors:  David R Spigel; Dianna L Shipley; David M Waterhouse; Suzanne F Jones; Patrick J Ward; Kent C Shih; Brian Hemphill; Michael McCleod; Robert C Whorf; Ray D Page; Joseph Stilwill; Tarek Mekhail; Cindy Jacobs; Howard A Burris; John D Hainsworth
Journal:  Oncologist       Date:  2019-08-16

2.  Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic injury.

Authors:  Volker Fendrich; Frederike Jendryschek; Saskia Beeck; Max Albers; Matthias Lauth; Farzad Esni; Kristin Heeger; Janina Dengler; Emily P Slater; Julia P N Holler; Aninja Baier; Detlef K Bartsch; Jens Waldmann
Journal:  Oncogene       Date:  2018-01-25       Impact factor: 9.867

3.  A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.

Authors:  Andrew H Ko; Patrick B Murphy; James D Peyton; Dianna L Shipley; Ahmed Al-Hazzouri; Francisco A Rodriguez; Mark S Womack; Henry Q Xiong; David M Waterhouse; Margaret A Tempero; Shuangli Guo; Cassie M Lane; Chris Earwood; Laura M DeBusk; Johanna C Bendell
Journal:  Oncologist       Date:  2017-09-21

4.  SPARC overexpression suppresses radiation-induced HSP27 and induces the collapse of mitochondrial Δψ in neuroblastoma cells.

Authors:  Smita Tanpure; Jerusha Boyineini; Manu Gnanamony; Reuben Antony; Karen S Fernández; Jaime Libes; Julian Lin; David Pinson; Pushpa A Joseph; Christopher S Gondi
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

5.  MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.

Authors:  Yong Lin; Xin Ge; Yiyang Wen; Zhu-Mei Shi; Qiu-Dan Chen; Min Wang; Ling-Zhi Liu; Bing-Hua Jiang; Yuan Lu
Journal:  Oncotarget       Date:  2016-10-25

Review 6.  Targeting Heat Shock Protein 27 in Cancer: A Druggable Target for Cancer Treatment?

Authors:  Seul-Ki Choi; Heejin Kam; Kye-Young Kim; Suk In Park; Yun-Sil Lee
Journal:  Cancers (Basel)       Date:  2019-08-16       Impact factor: 6.639

Review 7.  Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy.

Authors:  Chul Won Yun; Hyung Joo Kim; Ji Ho Lim; Sang Hun Lee
Journal:  Cells       Date:  2019-12-24       Impact factor: 6.600

Review 8.  The Role of Hsp27 in Chemotherapy Resistance.

Authors:  Marios Lampros; Nikolaos Vlachos; Spyridon Voulgaris; George A Alexiou
Journal:  Biomedicines       Date:  2022-04-14

Review 9.  The Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic Cancer.

Authors:  Mitsuru Okuno; Seiji Adachi; Osamu Kozawa; Masahito Shimizu; Ichiro Yasuda
Journal:  Int J Mol Sci       Date:  2016-01-21       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.